ATE500819T1 - Stabilisierte pharmazeutische feste zusammensetzungen von arzneimitteln mit geringer löslichkeit, poloxameren und stabilisierenden polymeren - Google Patents

Stabilisierte pharmazeutische feste zusammensetzungen von arzneimitteln mit geringer löslichkeit, poloxameren und stabilisierenden polymeren

Info

Publication number
ATE500819T1
ATE500819T1 AT04806432T AT04806432T ATE500819T1 AT E500819 T1 ATE500819 T1 AT E500819T1 AT 04806432 T AT04806432 T AT 04806432T AT 04806432 T AT04806432 T AT 04806432T AT E500819 T1 ATE500819 T1 AT E500819T1
Authority
AT
Austria
Prior art keywords
solid compositions
poloxamers
low solubility
pharmaceutical solid
stabilizing polymers
Prior art date
Application number
AT04806432T
Other languages
English (en)
Inventor
Marshall David Crew
Ravi Mysore Shanker
Daniel Tod Smithey
Warren Kenyon Miller
Dwayne Thomas Friesen
Original Assignee
Bend Res Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bend Res Inc filed Critical Bend Res Inc
Application granted granted Critical
Publication of ATE500819T1 publication Critical patent/ATE500819T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AT04806432T 2003-12-31 2004-12-20 Stabilisierte pharmazeutische feste zusammensetzungen von arzneimitteln mit geringer löslichkeit, poloxameren und stabilisierenden polymeren ATE500819T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53384803P 2003-12-31 2003-12-31
PCT/IB2004/004260 WO2005065656A2 (en) 2003-12-31 2004-12-20 Stabilized pharmaceutical solid compositions of low-solubility drugs, poloxamers, and stabilizing polymers

Publications (1)

Publication Number Publication Date
ATE500819T1 true ATE500819T1 (de) 2011-03-15

Family

ID=34748971

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04806432T ATE500819T1 (de) 2003-12-31 2004-12-20 Stabilisierte pharmazeutische feste zusammensetzungen von arzneimitteln mit geringer löslichkeit, poloxameren und stabilisierenden polymeren

Country Status (9)

Country Link
US (1) US20070148232A1 (de)
EP (1) EP1701703B1 (de)
JP (1) JP2007517015A (de)
AT (1) ATE500819T1 (de)
BR (1) BRPI0418294A (de)
CA (1) CA2551254A1 (de)
DE (1) DE602004031767D1 (de)
MX (1) MXPA06007512A (de)
WO (1) WO2005065656A2 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008511607A (ja) * 2004-08-31 2008-04-17 ファイザー・プロダクツ・インク 低溶解性薬物および重合体を含む医薬投与剤形
RU2382648C2 (ru) * 2004-12-03 2010-02-27 Мерк Энд Ко., Инк. Фармацевтический состав карбоксамидных ингибиторов интегразы вич, содержащий композицию с контролируемой скоростью высвобождения
US20090304786A1 (en) * 2005-11-25 2009-12-10 Viswaprasad Varanasi Stable Dosage Forms of an Antidepressant
GB0613925D0 (en) * 2006-07-13 2006-08-23 Unilever Plc Improvements relating to nanodispersions
TWI489984B (zh) 2006-08-04 2015-07-01 Wyeth Corp 用於非經腸道傳輸化合物之配方及其用途
PE20081506A1 (es) * 2006-12-12 2008-12-09 Infinity Discovery Inc Formulaciones de ansamicina
KR20080062430A (ko) * 2006-12-29 2008-07-03 에스케이케미칼주식회사 보관안정성이 우수한 아토르바스타틴 함유 경구투여용 제제
HRP20191104T1 (hr) 2007-09-25 2019-09-20 Solubest Ltd. Pripravci koji sadrže lipofilne aktivne spojeve i postupak za njihovu pripremu
SG174488A1 (en) * 2009-03-19 2011-10-28 Shionogi & Co Solid preparation containing npy y5 receptor antagonist
JP5654002B2 (ja) 2009-05-13 2015-01-14 ビーエーエスエフ ソシエタス・ヨーロピアＢａｓｆ Ｓｅ ポリエーテルに基づくコポリマーを微水溶性ポリマーと組み合わせて含む固体医薬調製物
BR112012006056A2 (pt) * 2009-09-18 2016-03-29 Basf Se forma de dosagem
AU2010313571B2 (en) 2009-10-26 2014-07-31 Merck Sharp & Dohme Llc Solid pharmaceutical compositions containing an integrase inhibitor
EP2366378A1 (de) 2010-03-01 2011-09-21 Dexcel Pharma Technologies Ltd. Donepezilformulierungen mit verzögerter Freisetzung
TWI605814B (zh) 2010-03-11 2017-11-21 惠氏有限責任公司 甲基拿淬松（ｍｅｔｈｙｌｎａｌｔｒｅｘｏｎｅ）之口服製劑及親脂性鹽
DE102012105512A1 (de) * 2012-06-25 2014-04-24 Hennig Arzneimittel Gmbh & Co. Kg Arzneiform zur verlängerten Freisetzung von Wirkstoffen
CN104721141A (zh) * 2013-12-18 2015-06-24 博瑞生物医药技术(苏州)有限公司 抗真菌药物固体分散体
WO2016004369A1 (en) 2014-07-02 2016-01-07 The Research Foundation For The State University Of New York Surfactant-stripped micelle compositions with high cargo to surfactant ratio
US20160200925A1 (en) * 2015-01-08 2016-07-14 Canon Kabushiki Kaisha Image recording method, ink, and liquid composition
GB2584341B (en) * 2019-05-31 2023-03-01 Gw Res Ltd Cannabinoid formulations

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6368622B2 (en) * 1999-01-29 2002-04-09 Abbott Laboratories Process for preparing solid formulations of lipid regulating agents with enhanced dissolution and absorption
ES2307482T3 (es) * 1999-02-10 2008-12-01 Pfizer Products Inc. Dispersiones farmaceuticas solidas.
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6395300B1 (en) * 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
US6264981B1 (en) * 1999-10-27 2001-07-24 Anesta Corporation Oral transmucosal drug dosage using solid solution
JP2004500358A (ja) * 1999-12-08 2004-01-08 ファルマシア　コーポレイション バイオアベイラビリティーが増加した固体状態のセレコキシブ
US20010036959A1 (en) * 2000-04-03 2001-11-01 Gabel Rolf Dieter Carvedilol-hydrophilic solutions
AU2001257115B2 (en) * 2000-04-20 2005-01-27 Rtp Pharma Inc. Improved water-insoluble drug particle process
US6316029B1 (en) * 2000-05-18 2001-11-13 Flak Pharma International, Ltd. Rapidly disintegrating solid oral dosage form
KR20020014570A (ko) * 2000-08-18 2002-02-25 김충섭 고체분산화시킨 무정형 이프리플라본의 제조방법
BR0307332A (pt) * 2002-02-01 2004-12-07 Pfizer Prod Inc Formas de dosagem farmacêuticas de liberação controlada de um inibidor da proteìna de transferência do éster de colesterol
PL372247A1 (en) * 2002-02-01 2005-07-11 Pfizer Products Inc. Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus
GB2394417A (en) * 2002-10-24 2004-04-28 Novartis Ag Solid dispersion comprising a piperidine substance P antagonist and a carrier

Also Published As

Publication number Publication date
DE602004031767D1 (de) 2011-04-21
BRPI0418294A (pt) 2007-05-02
WO2005065656A2 (en) 2005-07-21
MXPA06007512A (es) 2006-08-31
US20070148232A1 (en) 2007-06-28
CA2551254A1 (en) 2005-07-21
EP1701703A2 (de) 2006-09-20
WO2005065656A3 (en) 2006-07-13
JP2007517015A (ja) 2007-06-28
EP1701703B1 (de) 2011-03-09

Similar Documents

Publication Publication Date Title
DE602004031767D1 (de) Stabilisierte pharmazeutische feste zusammensetzungen von arzneimitteln mit geringer löslichkeit, poloxameren und stabilisierenden polymeren
ATE444060T1 (de) Pharmazeutische zusammensetzungen enthaltend dispersionen aus arzneistoffen und neutralen polymeren
DE60220049D1 (de) Pharmazeutische zusammensetzungen enthaltend eine feste dispersion eines im wasser schwerlöslichen arzneimittels und ein löslichkeitsteigerndes polymer
EA200201254A1 (ru) Высококонцентрированные стабильные растворы мелоксикама
CY1109861T1 (el) Διαδερμικο θεραπευτικο συστημα για την ασθενεια του παρκινσον που προκαλει υψηλα επιπεδα πλασματος της ροτιγοτινης
ATE409462T1 (de) Pharmazeutische zusammensetzungen mit verbesserter leistung enthaltend ein hpmca polymer
ATE356612T1 (de) Orale, pharmazeutische darreichungsformen von flüssigen medikamenten mitverbesserter bioverfügbarkeit
EA200200431A1 (ru) Фармацевтические композиции, обеспечивающие повышенные концентрации лекарства
WO2005084639A3 (en) Polymeric drug delivery system for hydrophobic drugs
MXPA06012583A (es) Nanoparticulas pegiladas.
AR044926A1 (es) Sistema de suministro de farmacos gelificante in situ
PE20040103A1 (es) Metodo y formas de dosificacion para incrementar la solubilidad de composiciones de farmaco para administracion controlada
JP2005511720A (ja) 無針注射用の安定な高濃度メロキシカム溶液
PE20040865A1 (es) Composiciones farmaceuticas de farmacos semiordenados y polimeros
DK1256343T3 (da) Flibanserin til behandlingen af extrapyramidale bevægelseslidelser
DE60313359D1 (de) Fenofibratsäure enthaltende pharmazeutische zusammensetzung und deren physiologisch verträgliche salze und derivate
RU2016139373A (ru) Растворы бупренорфина с замедленным высвобождением
ES2625873T3 (es) Método de preparación de micropartículas biodegradables que contienen fármacos
DK1105102T3 (da) Injicerbart farmaceutisk præparat på basis af et farmaceutisk acceptabelt salt af clopidogrel eller ticlopidin
BRPI0514753A (pt) formas de dosagem farmacêutica compreendendo um medicamento de baixa solubilidade e um polìmero
AR036877A1 (es) Formulacion farmaceutica
SE9301877D0 (sv) In situ gel for therapeutic use
Patel et al. Formulation Evaluation and optimization Of stomach specific in situ gel of Ranitidine hydrochloride
CR8059A (es) Composicion farmaceutica en forma de hidrogel para administracion transdermica de sustancias activas
ES2188513T3 (es) Utilizacion de desoxipeganina para el tratamiento de la drogodependencia.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties